Cargando…
A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy
We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855735/ https://www.ncbi.nlm.nih.gov/pubmed/27111877 http://dx.doi.org/10.1016/j.ijscr.2016.04.013 |
_version_ | 1782430402770632704 |
---|---|
author | Nitta, Toshikatsu Fujii, Kensuke Kataoka, Jun Tominaga, Tomo Kawasaki, Hiroshi Ishibashi, Takashi |
author_facet | Nitta, Toshikatsu Fujii, Kensuke Kataoka, Jun Tominaga, Tomo Kawasaki, Hiroshi Ishibashi, Takashi |
author_sort | Nitta, Toshikatsu |
collection | PubMed |
description | We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pancreatic and common bile ducts caused by a mass-neighboring cyst. Based on these findings, we performed subtotal stomach-preserving pancreaticoduodenectomy. The patient demonstrated a good postoperative course, and was discharged from our hospital in remission 49 days after the surgery. Pathological findings confirmed that it was anaplastic pancreas carcinoma (giant cell type). After the surgery, we performed S-1 adjuvant chemotherapy 100 mg/day for four weeks, repeated similarly every six weeks for a total of four courses. We have followed this case for over 2 years so far with adjuvant chemotherapy, and no recurrence or metastasis has been revealed. Adjuvant chemotherapy with S-1 in patients with resected anaplastic carcinoma of the pancreas is also recommended as a result of Japan Adjuvant Study Group of Pancreatic Cancer 01(JASPAC-01) like the ordinary pancreatic ductal carcinomas. There is a possibility to achieve long-term survival in cases in which multidisciplinary treatment such as a curative resection and adjuvant chemotherapy are performed. |
format | Online Article Text |
id | pubmed-4855735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-48557352016-05-24 A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy Nitta, Toshikatsu Fujii, Kensuke Kataoka, Jun Tominaga, Tomo Kawasaki, Hiroshi Ishibashi, Takashi Int J Surg Case Rep Case Report We herein describe the case of a 70-year-old female patient diagnosed with pancreatic carcinoma. An abdominal enhanced computed tomography scan revealed a poorly enhanced mass (17 mm × 15 mm in size) in the pancreatic head. Magnetic resonance cholangiopancreatography revealed stenosis of the main pancreatic and common bile ducts caused by a mass-neighboring cyst. Based on these findings, we performed subtotal stomach-preserving pancreaticoduodenectomy. The patient demonstrated a good postoperative course, and was discharged from our hospital in remission 49 days after the surgery. Pathological findings confirmed that it was anaplastic pancreas carcinoma (giant cell type). After the surgery, we performed S-1 adjuvant chemotherapy 100 mg/day for four weeks, repeated similarly every six weeks for a total of four courses. We have followed this case for over 2 years so far with adjuvant chemotherapy, and no recurrence or metastasis has been revealed. Adjuvant chemotherapy with S-1 in patients with resected anaplastic carcinoma of the pancreas is also recommended as a result of Japan Adjuvant Study Group of Pancreatic Cancer 01(JASPAC-01) like the ordinary pancreatic ductal carcinomas. There is a possibility to achieve long-term survival in cases in which multidisciplinary treatment such as a curative resection and adjuvant chemotherapy are performed. Elsevier 2016-04-23 /pmc/articles/PMC4855735/ /pubmed/27111877 http://dx.doi.org/10.1016/j.ijscr.2016.04.013 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Nitta, Toshikatsu Fujii, Kensuke Kataoka, Jun Tominaga, Tomo Kawasaki, Hiroshi Ishibashi, Takashi A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title_full | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title_fullStr | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title_full_unstemmed | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title_short | A case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after S1 postoperative adjuvant chemotherapy |
title_sort | case of long-term 24-month survival in pancreatic anaplastic carcinoma (giant cell type) after s1 postoperative adjuvant chemotherapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855735/ https://www.ncbi.nlm.nih.gov/pubmed/27111877 http://dx.doi.org/10.1016/j.ijscr.2016.04.013 |
work_keys_str_mv | AT nittatoshikatsu acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT fujiikensuke acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT kataokajun acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT tominagatomo acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT kawasakihiroshi acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT ishibashitakashi acaseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT nittatoshikatsu caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT fujiikensuke caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT kataokajun caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT tominagatomo caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT kawasakihiroshi caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy AT ishibashitakashi caseoflongterm24monthsurvivalinpancreaticanaplasticcarcinomagiantcelltypeafters1postoperativeadjuvantchemotherapy |